manilatimes9d
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates
Recently, AIM announced a comprehensive deployment to integrate the DeepSeek large model, particularly in vaccine development, utilizing DeepSeek in conjunction with generative models and deep ...
FierceBiotech21d
Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader
The phase 3 study assessed vepdegestrant against AstraZeneca’s hormone med Faslodex in 624 patients with ER+/HER2- advanced or metastatic breast cancer who had already tried CDK 4/6 inhibitors ...
clinicaltrialsarena22d
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Credit: Shutterstock / Maria Sbytova. Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it ...
C&EN24d
Controlling Protein Immobilization over Poly(3-hydroxybutyrate) Microparticles Using Substrate Binding Domain from PHA Depolymerase
For the HEK293 F expression of RBD-SBD, it was cloned into pCDNA 3.1(+) between T7 and His-tag sequences. The construct contained the IL-2 signal peptide (AAB86861.1) for protein secretion. The final ...
Oncology Nurse Advisor28d
Disitamab Vedotin Plus Toripalimab Demonstrates Activity in HER2-Expressing MIBC
The pathologic complete response rate was 63.6%, and the pathologic response rate was 75.8%. Neoadjuvant disitamab vedotin plus perioperative toripalimab has demonstrated efficacy in patients with ...
Daily29d
AstraZeneca-Daiichi Sankyo Enhertu recommended for approval in EU for patients with HER2-low or HER2-ultralow metastatic breast cancer
In the trial, Enhertu showed a 38% reduction in the risk of disease progression or death versus chemotherapy (hazard ratio [HR] 0.62; confidence interval [CI] 0.52-0.75; p<0.0001) in patients with ...
FierceBiotech29d
Frazier arms Callio with $187M series A to fly Hummingbird's HER2 dual payload ADC to clinic
Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload antibody-drug conjugate that’s ready for the clinic. The ADC ...
Domain2mon
36 Westport Parade, Darch WA 6065
Congratulations to our very valued clients - and also to our very lucky buyers on securing this beautiful home! :) Step into a home where space meets style - Nestled in the sought-after Ashdale ...
Business Standard5mon
Jio Hotstar domain: Website acquired by new owners; it's not Reliance
The battle over the Jio Hotstar domain has taken an unexpected turn, with the website now acquired by two Dubai-based siblings, Jainam and Jivika, days after its original owner—a Delhi-based anonymous ...
Domain9mon
Inspiring confidence in life’s property decisions
Domain Group is a leading Australian property marketplace made-up of a portfolio of brands. We are united in our Purpose to inspire confidence in life’s property decisions. Our brands offer ...
Frontiers1y
Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma
Trastuzumab is a monoclonal humanized anti-HER2 mAb which binds to domain IV of the extracellular segment and blocks the cleavage of the extracellular domain of HER2. The binding of Trastuzumab will ...